PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31673231-6	2019	Combined treatment of TRAIL with bortezomib resulted in strong synergistic response with enhanced activation of caspases-8, -9 and -3, and increased Annexin V-binding cell fractions in TRAIL-resistant SNU-216 cells.	bortezomib	33-43	TNF superfamily member 10	Homo sapiens	22-27	
31673231-6	2019	Combined treatment of TRAIL with bortezomib resulted in strong synergistic response with enhanced activation of caspases-8, -9 and -3, and increased Annexin V-binding cell fractions in TRAIL-resistant SNU-216 cells.	bortezomib	33-43	TNF superfamily member 10	Homo sapiens	185-190	
31673231-12	2019	In summary, upregulation of DR5 by bortezomib is of critical significance in the synergy of bortezomib with TRAIL in apoptosis of TRAIL-resistant SNU-216 and that activity of ERK1/2 is required in the bortezomib-induced DR5 overexpression.	bortezomib	35-45	TNF superfamily member 10	Homo sapiens	108-113	
31673231-12	2019	In summary, upregulation of DR5 by bortezomib is of critical significance in the synergy of bortezomib with TRAIL in apoptosis of TRAIL-resistant SNU-216 and that activity of ERK1/2 is required in the bortezomib-induced DR5 overexpression.	bortezomib	35-45	TNF superfamily member 10	Homo sapiens	130-135	
31673231-12	2019	In summary, upregulation of DR5 by bortezomib is of critical significance in the synergy of bortezomib with TRAIL in apoptosis of TRAIL-resistant SNU-216 and that activity of ERK1/2 is required in the bortezomib-induced DR5 overexpression.	bortezomib	92-102	TNF superfamily member 10	Homo sapiens	130-135	
31673231-12	2019	In summary, upregulation of DR5 by bortezomib is of critical significance in the synergy of bortezomib with TRAIL in apoptosis of TRAIL-resistant SNU-216 and that activity of ERK1/2 is required in the bortezomib-induced DR5 overexpression.	bortezomib	92-102	TNF superfamily member 10	Homo sapiens	130-135